Brief: Athira Pharma Doses First Subject In Phase 1 Clinical Trial Of HGF/MET Positive Modulator, ATH-1020, An Orally Available Small Molecule For Neuropsychiatric Conditions

LeonaBio

04/04/2022 12:20

April 4 (Reuters) - Athira Pharma Inc  ATHA.O :
    * ATHIRA PHARMA DOSES FIRST SUBJECT IN PHASE 1 CLINICAL
TRIAL OF
HGF/MET POSITIVE MODULATOR, ATH-1020, AN ORALLY AVAILABLE SMALL
MOLECULE FOR NEUROPSYCHIATRIC CONDITIONS

Source text for Eikon:  ID:nGNX8K0zbq 
Further company coverage:  ATHA.O 

 ((Reuters.Briefs@thomsonreuters.com;))